Third-quarter results for Medtronic (NYSE:MDT) included a timeline for a planned label expansion for its automated insulin ...

The global Insulin Delivery Devices Market was valued at USD 30.9 billion in 2022 and is expected to grow significantly, ...

Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated ...

Medtronic beat Wall Street estimates for third-quarter profit on Tuesday, partly helped by demand for its diabetes devices, ...

The fully automated BPS_RL technology integrates with the existing Automated Insulin Delivery Adaptive NETwork (AIDANET) — a ...

People with type 1 diabetes require continuous insulin treatment and must regularly measure their glucose levels. With ...

People with type 1 diabetes require continuous insulin treatment and must regularly measure their glucose levels. With open-loop therapies, insulin administration is manually controlled, while hybrid ...

JAMA today published outcomes from a study evaluating the safety and efficacy of the Insulet Omnipod 5 in adults with type 2 ...

For people living with Type 1 Diabetes (T1D), keeping blood sugar levels in check is a constant challenge. A new clinical trial at UVA is aiming to ...

Medtronic plc reported third-quarter fiscal 2025 earnings that beat analyst estimates, while revenue fell short of ...